<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Choice of influenza vaccine for children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Choice of influenza vaccine for children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Choice of influenza vaccine for children</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Category</td> <td class="subtitle1">Type of influenza vaccine</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Age</td> </tr> <tr> <td class="indent1"> <ul> <li>0 through 5 months</li> </ul> </td> <td> <ul> <li>Influenza vaccine not licensed for this age group</li> <li>Vaccination of mothers with IIV during pregnancy can provide protection for the infant</li> <li>Household contacts and out-of-home caregivers should receive IIV or LAIV*</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>6 through 23 months</li> </ul> </td> <td> <ul> <li>IIV (LAIV not licensed for this age group)</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>≥24 months</li> </ul> </td> <td> <ul> <li>IIV or LAIV*</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Chronic medical disorders</td> </tr> <tr> <td class="indent1"> <ul> <li>Age 2 through 4 years and any of the following<sup>¶</sup>: <ul> <li>A diagnosis of asthma</li> <li>Parent- or caregiver-reported wheezing or asthma verified by a health care provider in the previous 12 months</li> <li>Documented wheezing in the previous 12 months</li> </ul> </li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Weakened immune system due to disease (eg, HIV, AIDS, cancer), medication (eg, chronic glucocorticoids), or anatomic or functional asplenia (eg, sickle cell disease)<sup>¶</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Children &lt;19 years of age who are receiving long-term aspirin therapy<sup>¶</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Asthma in children ≥5 years<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Neurologic, neuromuscular, and neurodevelopmental conditions (eg, cerebral palsy, epilepsy, stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, spinal cord injury)<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Chronic lung disease (eg, cystic fibrosis)<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Heart disease (eg, congenital heart disease, pulmonary hypertension)<sup>Δ</sup>; excludes isolated systemic hypertension</li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Blood disorders<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Endocrine disorders (eg, diabetes mellitus)<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Kidney disorders<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Liver disorders<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Metabolic disorders (eg, inherited metabolic disorders, mitochondrial disorders)<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Class III obesity (BMI ≥40 for adults or BMI <span class="nowrap_whitespace">&gt;95<sup>th</sup></span> percentile value for children &lt;18 years)<sup>◊</sup></li> </ul> </td> <td> <ul> <li>IIV or LAIV*</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine<sup>Δ</sup><sup>§</sup></li> </ul> </td> <td> <ul> <li>Precaution for influenza vaccination with IIV or LAIV<sup>¥</sup></li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Other conditions</td> </tr> <tr> <td class="indent1"> <ul> <li>Pregnancy<sup>¶</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>History of severe allergic reaction to any component of the vaccine or after a previous dose of any influenza vaccine<sup>¶</sup><sup>‡</sup><sup>†</sup></li> </ul> </td> <td> <ul> <li>Contraindication for influenza vaccination with LAIV or IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>CSF leak or cochlear implant<sup>¶</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Receipt of oseltamivir or zanamivir in past 48 hours, receipt of peramivir in past 5 days, or receipt of baloxavir in past 17 days<sup>¶</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Close contact of person who is severely immunosuppressed and requires a protected environment<sup>¶</sup></li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Household or close contact of an infant &lt;6 months of age or of an individual with chronic medical disorder or other condition with increased risk of severe or complicated influenza infection <strong>except</strong> severely immunocompromised person who requires protected environment</li> </ul> </td> <td> <ul> <li>IIV or LAIV*</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Resident of long-term care facility</li> </ul> </td> <td> <ul> <li>IIV</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Native Americans, including Alaska Natives</li> </ul> </td> <td> <ul> <li>IIV or LAIV*</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>IIV: inactivated influenza vaccine; LAIV: live attenuated influenza vaccine; BMI: body mass index; CSF: cerebrospinal fluid.</p>
<p>* LAIV may be administered to individuals who are healthy, nonpregnant, and 2 through 49 years of age.</p>
<p>¶ Contraindication to LAIV.</p>
<p>Δ Precaution for LAIV.</p>
<p>◊ Refer to UpToDate content on obesity in children for details.</p>
<p>§ Precaution for IIV.</p>
<p>¥ It is not known whether Guillain-Barré syndrome increases the risk of Guillain-Barré syndrome in children who developed Guillain-Barré syndrome within 6 weeks after a dose of influenza vaccine. The theoretic risk should be balanced against the potential morbidity and mortality of influenza infection.</p>
<p>‡ Contraindication for IIV.</p>
† Although the prescribing information for LAIV includes severe allergic reaction to egg as a contraindication, the Advisory Committee on Immunization Practices and the American Academy of Pediatrics recommend any licensed vaccine that is appropriate for age and health status for individuals with egg allergy of any severity.</div><div class="graphic_reference">Reference:
<ol>
<li>Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023-24 influenza season. MMWR Recomm Rep 2023; 72:1.</li>
</ol></div><div id="graphicVersion">Graphic 67562 Version 23.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
